Supported via arm's length funding from Gilead.
Using genomic profiling to match treatment improves survival outcomes for certain patients with metastatic breast cancer
Both exemestane and tamoxifen added to OFS sustain reduction in distant recurrence and death in patients with hormone receptor-positive (HR+) early breast cancer
MONALEESA trials: overall survival in patients with HR+/ HER2- advanced breast cancer by subtype, metastasis site and more
DESTINY-Breast03 trial: survival outcomes with T-DXd versus T-DM1 in patients with HER2+ unresectable or metastatic breast cancer
Updated overall survival results from the phase III PHOEBE trial in HER2+ metastatic breast cancer
Top image: rustycloud
The content and interpretation of these conference highlights are the views and comments of the speakers/ authors.